Absorption enhancing excipients in systemic nasal drug delivery

Journal of Excipients and Food Chemicals

Volumn 5, Issue 2, 2014, Pages 100-112

  Maggio, Edward T ^a  

^a Aegis Therapeutics LLC   (United States)

Author keywords

Absorption enhancer; Alkylsaccharide; Chitosan; Cyclodextrin; Drug delivery; Intranasal

Indexed keywords

ALKYLGLYCOSIDE; BENZALKONIUM CHLORIDE; BILE SALT; CHITOSAN; CYCLODEXTRIN; DEOXYCHOLIC ACID; DIAZEPAM; DODECYL MALTOSIDE; EXCIPIENT; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLYCOCHOLIC ACID; GLYCOSIDE; POLIDOCANOL; SUMATRIPTAN; TAUROCHOLIC ACID; TAURODIHYDROFUSIDIC ACID; UNCLASSIFIED DRUG;

COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; GEL; HUMAN; HYDROLYSIS; MOLECULAR WEIGHT; NONHUMAN; NOSE CAVITY; NOSE IRRITATION; PHYSIOLOGICAL PROCESS; PRESCRIPTION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING;

EID: 84903398472     PISSN: None     EISSN: 21502668     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Neurelis announces positive results from phase 1 pharmacokinetic study of NRL-01 (intranasal diazepam) http://www.prnewswire.com/newsreleases/ neurelis-announces-positive-results-fromphase-1-pharmacokinetic-study-of-nrl-01-intranasaldiazepam-123834469.html (accessed 17April 2014).
2. Maggio ET. Alkylglycoside compositions for drug administration. US Patent No. 8,268,791, Issued Sept. 18, 2012.
3. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J. Pharm. Sci., 93(9):2205-13, 2004.
4. Maggio ET, Meezan E, Ghambeer DKS, Pillion DJ. High bioavailability formulation of salmon calcitonin-potential opportunities for expanded use in analgesia. Drug Deliv. Technol., 10:58-63, 2010.
5. Mygind N, Änggård A., Anatomy and physiology of the nose-pathophysiologic alterations in allergic rhinitis. Clin Rev Allergy. 2:173-188, 1984.
6. Illum L., Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci., 11(1):1-18, 2000.
7. Schipper NGM., Verhoef JC, Merkus FWHM. The nasal mucocilliary clearance: relevance to nasal drug delivery. Pharm Res., 8:807-814, 1991.
8. Mathison S, Nagilla R, Kompella UB., Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 5:415-441, 1998.
9. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature, 417 (6888): 552-5, 2002.
10. Chien YW, Su KSE, Chang S. Nasal Systemic Drug Delivery. New York: Marcel Dekker, Inc, 1989:1-38.
11. Rothe H, Fautz R, Gerber E, Neumann L, Rettinger K, Schuh W, Gronewold C. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. Toxicol. Lett., 205(2):97 104, 2011.
12. Hatch TF. Distribution and deposition of inhaled particles in respiratory tract. Bacteriol. Rev. 25:237 240, 1961.
13. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J. Aerosol. Sci., 17(5):811-825,1986.
14. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect., 113(7):823-839, 2005.
15. England RJ, Homer JJ, Knight LC, Ell SR. Nasal pH measurement: a reliable and repeatable parameter. Clin. Otolaryngol. Allied Sci., 24(1):67-8, 1999.
16. Behl CR, Pimplaskar HK, Sileno AP, deMeireles J, Romeo VD. Effects of physiochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Delivery Rev., 29:89-116, 1998.
17. Marttin E, Verhoef JC, Cullander C, Romeijn SG, Nagelkerke JF, Merkus FWHM. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers. Pharm Res., 14:631-637, 1997.
18. Morimoto K, Yamaguchi H, Iwakura Y, Miyazaki M, Nakatani E, Iwamoto T, Ohashi Y, Nakai Y. Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Pharm. Res. 18(9):1175-9, 1991.
19. Green K. 1993 The effects of preservatives on corneal permeability of drugs. In Biopharmaceutics of Ocular Drug Delivery, ed Edman P. 43 Boca Raton, FL: CRC Press.
20. Kagatani S, Hasumi S, Sonobe T, Aruga M. Pharmaceutical compositions for nasal administration comprising calcitonin and an absorption-promoting substance US Patent No. 4,690,952 (1987).
21. Tomita, M., Hayashi M, Awazu.S. Absorptionenhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. J. Pharm. Sci. 85(6): 608-611, 1996.
22. Chen-Quay S-C, Eiting KT, Li A, Lamharzin, Quay SC. Identification of Tight Junction Modulating Lipids. J Pharm Sci., 98(2):606-19, 2009.
23. Davis SS, Illum I. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet. 42(13): 1107-1128, 2003.
24. Chavanpatil MD, Vavia PR. Nasal drug delivery of sumatriptan succinate. Pharmazie. 60(5):347-9, 2005.
25. Donovan, MD, Flynn GL, Amidon GL. The Molecular Weight Dependence of Nasal Absorption: The Effect of Absorption Enhancers. Pharmaceutical Research 7 (8): 808-815, 1990.
26. Bagger MA, Nielsen HW, Bechgaard E. Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. Eur. J. Pharm. Sci. 14(1):69-74, 2001.
27. Mishima M, Okada S, Wakita Y, Nakano M. Promotion of nasal absorption of insulin by glycyrrhetinic acid derivatives. I. J. Pharmacobiodyn. 12(1):31-6, 1989.
28. Sinswat P, Tengamnuay P. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison of hydroxyl propyl and dimethylbeta-cyclodextrins. Int. J. Phar. 257:15-22, 2003.
29. Aungst BJ, Rogers NJ. Site dependence of absorption-promoting actions of laureth-9, Na salicylate, Na2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery. Pharm. Res. 5:305-8, 1998.
30. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284(1):362-9, 1998.
31. Kagatani S, Shinoda T, Fukui M, Ohmura T, Hasumi S, Sonobe T. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharm. Res. 13(5):739-43, 1996.
32. Wang H, Xu W, M. Effect of l-menthol pretreated nasal cavity on insulin pharmacological bioavailability. Chinese Pharmacological Bulletin;2002-01, 2002.
33. Parmar VJ, Lumbhani AN. Formulation and development of thermo-reversible mucoadhesive intranasal in situ hydrogel by using a combination of polymers. Bull. Pharmaceut. Res. 2(3):167-74, 2012.
34. Lin H, Gebhardt M, Bianc S, Kwond KA., Shima CK, Chunga S-J, Kima D-D. Enhancing effect of surfactants on fexofenadine HCl transport across the human nasal epithelial cell monolayer. Int. J. Pharmaceut. 330: 23-31, 2007.
35. Ohtake K, Natsume H, Ueda H, Morimoto Y. Analysis of transient and reversible effects of poly-Larginine on the in vivo nasal absorption of FITCdextran in rats. J. Control. Release. 82(2-3):263-75, 2002.
36. Williams AC, Barry BW. Penetration enhancers. Adv. Drug Deliv. Rev. 56(5):603-18, 2004.
37. Pillion DJ, Amsden JA, Kensil CR, Recchia J Structure-function relationship among Quillaja saponins serving as excipients for nasal and ocular delivery of insulin. J. Pharm. Sci. 85(5):518-24, 1996.
38. Ando T, Maitani Y, Yamamoto T, Takayama K, Nagai T. Nasal insulin delivery in rabbits using soybean-derived sterylglucoside and sterol mixtures as novel enhancers in suspension dosage forms. Biol. Pharm. Bull. 21(8):862-5, 1998.
39. Ahsan F, Arnold JJ, Meezan E, Pillion DJ. Sucrose cocoate, a component of cosmetic preparation, enhances nasal and ocular peptide absorption, Int. J. Pharm., 251:195-203, 2003.
40. Yetkin G, Celebi N, Agabeyoglu I, Gokcora N. The effect of dimethyl-beta-cyclodextrin and sodium taurocholate on the nasal bioavailability of salmon calcitonin in rabbits, STP. Pharma. Sci., 9:249-53, 1999.
41. Gordon GS, Moses AC, Silver RD, Flier JS, Carey MC. Nasal absorption of insulin: enhancement by hydrophobic bile salts. Proc. Natl. Acad. Sci. USA, 82(21): 7419-7423, 1985.
42. Baldwin PA, Klingbeil CK, Grimm CJ, Longenecker JP. The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models. Pharm. Res., 7(5):547-552, 1990.
43. McMartin C, Hutchinson LEF, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci., 76:535-540, 1987.
44. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov. Today, 7:1184-89, 2002.
45. Aungst BJ, Rogers NJ, Shefter E. Comparison of nasal rectal buccal, sublingual, and intramuscular insulin in efficacy and the effects of a bile salt absorption enhancer. J. Pharm. Exp. Ther., 244:23-27, 1988.
46. Zhang Y, Zhang Q, Sun Y, Sun J, Wang X, Chen M. Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies. Biol. Pharm. Bull. 28(12): 2263-2267, 2005.
47. Donovan, MD, Huang Y. Large molecule particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv. Drug Del. Rev., 29, 147-155, 1998.
48. LeeVH, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst., 8, 91-92, 1991.
49. Wermeling DP, Miller JL, Rudy AC. Systemic intranasal drug delivery: concepts and applications. Drug Deliv. Tech., 2, 56, 2002.
50. Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus. Adv. Drug Deliv. Rev., 48:173-93, 2001.
51. Lutz KL, Siahaan TJ. Molecular structure of the apical junction complex and its contribution to the paracellular barrier. J. Pharm. Sci., 86, 977-84, 1997.
52. Agerholm C, Bastholm L, Johansen PB, Nielsen MH, Elling F. Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-L-alpha-phosphaidylcholine and alphacyclodextrins in rabbits. J. Pharm. Sci., 83, 1706-11, 1994.
53. Vllasaliu D, Shubber, S, Fowler R, Garnett M, Alexander C, Stolnik S, Epithelial toxicity of alkylglycosides surfactants. J. Pharm. Sci., 102(1):114-125, 2013.
54. Material Safety Data Sheet TEGOSOFT LSE 65 K SOFT Evonik Goldschmidt GmbH Version: 1.11 Date Issued: 01/21/2010 Gold-schmidtstr. 100 Essen, 05 45127.
55. Kocher K, Wiegand HJ. Toxicology and dermatology. In: Balzer D, editor. Surfactant science series, Vol. 91, Non ionic surfactants: alkylpolyglucosides. New York: Marcel Dekker; 2000. p. 365-83.
56. Sucrose esters of fatty acids and sucroglycerides (WHO Food Additives Series 40), The forty-ninth meeting of the Joint FAO/ WHO Expert Committee on Food Additives (JECFA) Geneva 1998. http://www.inchem.org/documents/ jecfa/ jecmono/v040je04.htm.
57. Weber N, Benning H. Metabolism of orally administered alkyl beta-glycosides in the mouse. J. Nutr., 114(2):247-54, 1984.
58. Federal register ref. CFR Part 180. Alkyl (C10-C16) polyglycosides; exemption from the requirement of a tolerance. Federal register 70(177), 54281-54286, 2005.
59. Ahsan F, Arnold JJ, Yang T, Meezan E, Schwiebert EM, Pillion DJ. Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-betacyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). European Journal of Pharmaceutical Sciences., 20:27-34, 2003.
60. Pillion DJ, Hosmer S, Meezan E. Dodecylmaltosidemediated nasal and ocular absorption of lyspro-Insulin: independence of surfactant action from peptide multimer dissociation. Pharm. Res., 15:1637-39, 1998.
61. Waldrop MA, Leinung MC, Lee DW, Grasso P. Intranasal delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycemic control, insulin sensitivity, and bone formation in leptin resistant C57BLK/6-m db\db mice. Diabetes Obes. Metab., 12(10):871-5, 2010.
62. Ahsan F, Arnold JJ, Meezan E, Pillion DJ. Mutual inhibition of the insulin absorption-enhancing properties of dodecylmaltoside and dimethyl-betacyclodextrin following nasal administration. Pharm. Res., 18: 608-14, 2001.
63. Pillion, DJ, Atchison JA, Gargiulo C, Wang RX, Wang P, Meezan E. Insulin delivery in nosedrops: new formulations containing alkylglycosides. Endocrinology, 135:2386-91, 1994.
64. Pillion DJ, Atchison JA, Meezan E. Alkylglycosides Enhance Systemic Absorption of insulin delivered topically to the rat eye. J. Pharmacol. Exp. Therp., 271:1274-80, 1994.
65. Pillion DJ, Ahsan F, Arnold JJ, Balusubramaniam BM, Pirana O, Meezan E. Synthetic long-chain alkylglycosides as enhancers of nasal insulin absorption. J. Pharm. Sci., 91: 1456-62, 2002.
66. Ashan, F, Arnold J Meezan E, Pillion DJ, Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm. Res., 18: 1742-46, 2001.
67. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins 2. In vivo drug delivery. J. Pharmaceut. Sci., 85:1142-69, 1996.
68. Merkus FW, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PH, Hermens WA, Schipper NG. Cyclodextrins in nasal drug delivery, Adv. Drug Del. Rev., 36:41-57, 1999.
69. Merkus FW, Verhoef J C, Romeijn SG, Schipper NG. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm. Res., 8:588-92, 1991.
70. Francis SA, Kelly JM, McCormack J, Rogers RA, Lai J, Schneeberger EE, Lynch RD. Rapid reduction of MDCK cell cholesterol by methyl-beta-cyclodextrin alters steady state transepithelial electrical resistance. Eur. J. Cell. Biol., 78:473-84, 1999.
71. Marttin E, Verhoef J C, Merkus FWHM. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target, 6:17-36, 1998.
72. Shao Z, Krishnamoorthy, R, Mitra K Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharm. Res., 9(9):1157-63, 1992.
73. Watanabe Y, Matsumoto Y, Kawamoto K, Yazawa S, Matsumoto M. Enhancing effect of cyclodextrins on nasal absorption of insulin and its duration in rabbits. Chem. Pharm. Bull. (Tokyo), 40(11):3100-3104, 1992.
74. Yang T, Hussain A, Paulson J, Abbruscato TJ Ahsan F. Cyclodextrins in nasal delivery of low-molecularweight heparins: in vivo and in vitro studies. Pharm. Res., 21:1127-36, 2004.
75. Illum L, Dodane V, Iqbal K. Chitosan technology to enhance the effectiveness of nasal drug delivery. Drug. Deliv. Tech., 2: 40, 2002.
76. Illum L. Chitosan and its use as a pharmaceutical excipient, Pharm. Res., 15: 1326-31, 1998.
77. Illum L, Farraj NF, Davis SS. Chitosan as a novel delivery system for peptide drugs. Pharm. Res., 11: 1186-89, 1994.
78. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm., 178: 55-65, 1999.
79. Aspden TJ, Illum L, Skaugrud O. Chitosan as a nasal delivery system: Evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models. Eur. J. Pharmaceut. Sci., 4: 23-31, 1996.
80. Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. Pharmaceut. Sci. Technol. Today, 1: 246-253, 1998.
81. Fernandez-Urrusuno, R. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharmaceut. Res., 16:1576-81, 1999.
82. Illum L, Watts P, Fisher AN, Jabbal GI, Davis SS. Novel chitosan based delivery systems for the nasal administration of a LHRH-analogue. STP Pharma. Sci., 10: 89-94, 2000.
83. Janes K A, Calvo P, Alonso M J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Del. Rev., 47:83-97, 2001.
84. Van der Lubben, IM et al. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharmaceut. Sci., 14, 201-207, 2001.
85. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, Smith A, Illum L. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharmaceut. Res., 19:998-1008, 2002.
86. Hinchcliffe, M, Jabbal-Gill, I, Smith, A. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep. J. Pharm. Pharmacol., 57, 681-687, 2005.
87. Artursson, P. et al., Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res., 11, 1358-61, 1994.
88. Schipper NGM, Romejin SG, Verhoef JC, Merkus FWHM. Nasal insulin delivery with dimethyl-betacyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations. Pharm. Res., 10(5):682-86, 1993.
89. Frauman AG, Jerums G, Louis WJ. Effects of intranasal insulin in non-obese type II diabetics Diabetes Research and Clinical Practice, 3:197-202, 1987.
90. Deurloo MJ, Hermens WA, Romeyn SG, Verhoef JC, Merkus FW. Absorption enhancement of intranasally administered insulin by sodium taurodihydrofusidate (STDHF) in rabbits and rats. Pharm. Res., 6:853-856, 1989.
91. Johansson F, Hjertberg E, Eirefelt S, Tronde A, Hultkvist Bengtsson U. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci., 17, 63-71, 2002.
92. Li Y, Shao Z, Mitra AK. Dissociation of insulin oligomers by bile salt micelles and its effect on alphachymotrypsin-mediated proteolytic degradation. Pharm. Res., 7:864-869, 1992.
93. Maggio ET. Alkylsaccharides: circumventing oxidative damage to biotherapeutics caused by polyoxyethylene-based surfactants. Ther. Deliv. 4(5):567-72, 2013.
94. Maggio ET. Polysorbates, peroxides, protein aggregation, and immunogenicity a growing concern. J. Excipients and Food Chem. 3 (2):45-53, 2012.
95. Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 16(10):1576-81, 1999.